Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637361 | 0.86 | KIT (0.45) | PTK2KITFLT3AURKALRRK2 | |
| SCHEMBL2037924 | 0.86 | KIT (0.42) | PTK2KITFLT3AURKALRRK2 | |
| SCHEMBL2029806 | 0.82 | LRRK2 (0.43) | PTK2KITFLT3AURKALRRK2 | |
| SCHEMBL2034467 | 0.82 | PTK2 (0.44) | PTK2KITFLT3LRRK2 | |
| SCHEMBL2029269 | 0.81 | PTK2 (0.48) | PTK2LRRK2ALK | |
| SCHEMBL2028827 | 0.81 | LRRK2 (0.42) | PTK2KITFLT3AURKALRRK2 | |
| SCHEMBL2032365 | 0.81 | LRRK2 (0.43) | PTK2LRRK2ALK | |
| SCHEMBL2035270 | 0.81 | EGFR (0.44) | PTK2FLT3LRRK2EGFRFGFR1 | |
| SCHEMBL2035832 | 0.81 | PTK2 (0.44) | PTK2KITFLT3LRRK2EGFR | |
| SCHEMBL2034806 | 0.80 | PTK2 (0.43) | PTK2KITFLT3LRRK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | PTK2 2/4885KIT 1208/4885FLT3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.